ArticleBreast cancer (Dove Medical Press)2026
Multi-Omics Characterization of ABHD12 Across Pan-Cancer and Validation of Its Role in Promoting Proliferation and Metastasis in Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: ABHD12 is linked to cancer and neurodegeneration; we systematically characterized its pan-cancer role and validated its oncogenic function in breast cancer (BRCA) to guide mechanistic studies. Methods: We integrated multi-omics data from TCGA, GTEx, and various public platforms to analyze expression, prognosis, genetic variations, methylation, immune infiltration, and drug resistance. In qRT-PCR, Western blot, functional assays (CCK-8, wound healing, colony formation), and a nude mouse xenograft model, were conducted to validate ABHD12's role in BRCA. Results: ABHD12 was significantly upregulated at both mRNA and protein levels across multiple cancers. High expression correlated with poorer overall survival in BRCA, GBM, LGG, LIHC, and UVM. It demonstrated strong to moderate diagnostic value. ABHD12 expression was associated with copy number variations (CNVs) across 23 cancers, but not with methylation. It also correlated with immune cell infiltration (especially with macrophage), tumor mutational burden, neoantigens, microsatellite instability, and immune-related genes in certain cancers, and was potentially linked to resistance to multiple chemotherapeutics. KEGG analysis indicated that ABHD12 may play a potential role in the AMPK pathway. In BRCA, ABHD12 was higher in tumors than normal tissues. Functional studies showed ABHD12 enhanced proliferation, invasion, and migration, while silencing suppressed these traits. In vivo, ABHD12-overexpressing cells formed larger tumors, confirming its tumor-promoting role. Conclusion: ABHD12 may act as an oncogene across multiple cancers, linked to poor prognosis, diagnostic potential, chemotherapy resistance, and immunotherapy response. Its dysregulation is driven by CNVs rather than promoter methylation. ABHD12 might modulate macrophage polarization via the AMPK signaling pathway, leading to the remodeling of the tumor immune microenvironment. In vitro and vivo studies confirm its pro-tumorigenic role in BRCA, highlighting ABHD12 as a multifunctional biomarker and a molecular nexus linking lipid metabolism, immunity, and treatment resistance-warranting further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.